[Underutilization of cardiovascular pharmacotherapy: how to pay for it?].
作者信息
Wehling M
机构信息
Institut für Klinische Pharmakologie Mannheim, Universität Heidelberg.
出版信息
Dtsch Med Wochenschr. 2004 Feb 13;129(7):330. doi: 10.1055/s-2004-818631.
PMID:14765334
Abstract
摘要
相似文献
1
[Underutilization of cardiovascular pharmacotherapy: how to pay for it?].
Dtsch Med Wochenschr. 2004 Feb 13;129(7):330. doi: 10.1055/s-2004-818631.
2
Drug treatment and cost of cardiovascular disease in Australia.
Cardiovasc Ther. 2009 Fall;27(3):164-72. doi: 10.1111/j.1755-5922.2009.00090.x.
3
Reducing drug usage and adverse effects. Part III: Cardiovascular disease and hyperlipidemia.
Health Care Food Nutr Focus. 2005 Jun;22(6):7-11.
4
Bibliography. Current world literature. Clinical trials.
Curr Opin Cardiol. 2008 Jul;23(4):407-21. doi: 10.1097/HCO.0b013e3283081beb.
5
[Pharmacologic prevention of cardiovascular diseases--2005].
Orv Hetil. 2005 May 15;146(20 Suppl 2):1122-31.
6
Letter by Kelland and Roberts regarding article, "Lipid management to reduce cardiovascular risk: a new strategy is required".
Circulation. 2008 Aug 12;118(7):e119. doi: 10.1161/CIRCULATIONAHA.108.779330.
7
[Methods of evaluating drug therapy, particularly in cardiovascular diseases].
Cesk Zdrav. 1984 Sep;32(8-9):361-5.
8
[Cardiovascular pharmacology].
Dtsch Med Wochenschr. 2004 Apr 8;129(15):799. doi: 10.1055/s-2004-822876.
9
[Secondary nutritional and drug prevention of cardiovasculopathies].
Recenti Prog Med. 1999 Mar;90(3):155-9.
10
[Lipid and blood pressure reduction for reduction of cardiovascular mortality].
Med Monatsschr Pharm. 2003 Jun;26(6):185.
Zotero 插件